{"slug":"what-are-peptides-neuropathy","verification":{"valid":true,"entries":2,"head":"513e243ee7eafe1cd341b360c6e5dc2c7081fd7fa3ab14001d9bbd37c57e1666"},"energy":{"passes":2,"tokens_in":35742,"tokens_out":3195,"tokens_total":38937,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"513e243ee7eafe1cd341b360c6e5dc2c7081fd7fa3ab14001d9bbd37c57e1666"},"provenance":[{"ts":"2026-06-29T21:52:50.194Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: What Are Peptides for Neuropathy\nSlug: what-are-peptides-neuropathy\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\",\"section_headings\":[\"What's breaking down\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from peptide_chains / drug_chains.\",\"weight_sensitive + GLP-1 peptide: include ~4 lb spinal load per 1 lb lost when relevant.\",\"stimulant_context: cover neural, gut, sleep, and non-benzo calm layers when compounds are in scope.\",\"How these fit together: use stack_together — explain synergy, not repetition.\"]}","response":"{\n  \"slug\": \"what-are-peptides-neuropathy\",\n  \"title\": \"What Are Peptides for Neuropathy\",\n  \"body\": \"## What's breaking down\\n\\nNeuropathy involves progressive damage to peripheral nerves. Axons lose integrity. Myelin sheaths thin. Blood flow to nerves drops. Inflammatory signals stay elevated. The body's natural repair systems cannot keep pace with ongoing breakdown from diabetes, injury, inflammation, or other triggers. This imbalance leaves nerves hypersensitive or numb. Pain signals fire without clear cause. Sensation fades in a length-dependent pattern, often starting in the feet.\\n\\nRepair pathways include growth factors that encourage axon regrowth. Anti-inflammatory signals that calm overactive immune cells in nerves. Structural proteins that rebuild nerve architecture. When these lag, symptoms persist. Peptides under study target specific steps in these pathways rather than only blocking pain signals.\\n\\n## How these fit together\\n\\nDifferent peptides address distinct layers of nerve degeneration. One activates a repair receptor that shifts inflamed tissue toward healing. Another shows axon regrowth signals in animal models of nerve cuts. A third improves vibration sense in people with diabetes-related nerve changes. These actions map onto separate parts of the breakdown: inflammation control, structural repair, and functional recovery. No single peptide covers every layer in current data.\\n\\n## What the evidence actually shows\\n\\nHuman data centers on two compounds. A randomized double-blind trial gave long-acting C-peptide weekly for 52 weeks to 250 people with type 1 diabetes and mild to moderate peripheral neuropathy. Vibration perception threshold improved 25 percent versus almost no change on placebo. Nerve conduction velocity and clinical neuropathy scores showed no difference from placebo. (source from Diabetes Care 2016)\\n\\nARA290 received testing in small fiber neuropathy linked to sarcoidosis and type 2 diabetes. In placebo-controlled studies, p","tokens_in":35742,"tokens_out":3195,"cost":0,"prev":"genesis","hash":"a95cee184303f2416add90dbb1aa27c2e92158fcce314e4175fbca361a6fe416"},{"ts":"2026-07-17T02:43:33.466Z","model":"owner","action":"voxel_divide","prompt":"","input":"what-are-peptides-neuropathy","response":"20 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"a95cee184303f2416add90dbb1aa27c2e92158fcce314e4175fbca361a6fe416","hash":"513e243ee7eafe1cd341b360c6e5dc2c7081fd7fa3ab14001d9bbd37c57e1666"}]}